Overall rank by patents
#38,617
Across all tracked assignees
USPTO PatentsView assignee record - 6 granted patents across 6 technology areas, active 2016–2022. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES).
The verdict
ALPS holds 6 US patents across 6 technology areas, rank #38,617 of 50,000 tracked assignees.
ALPS Pharmaceutical Ind. Co., Ltd. has been granted 6 US utility patents between 2016 and 2022, placing ALPS Pharmaceutical Ind. Co., Ltd. at rank #38,617 across all assignees tracked by PlainPatent. This portfolio spans 6 distinct Cooperative Patent Classification (CPC) subclasses, averaging 16.3 claims per patent with primary concentration in A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES). As a Foreign Corporation, ALPS Pharmaceutical Ind. Co., Ltd. is one of the more focused assignees in the PatentsView dataset. By volume, ALPS sits between Almalence, Inc. (6 patents, rank #38,613) and Altimate Medical Holdings, Inc. (6 patents, rank #38,621) - the closest US assignees by grant volume. The composite Innovation Score of 27.4/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 4 grants, compared with 2 in the 2015–2019 window, a +100% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. ALPS Pharmaceutical Ind. Co., Ltd.'s 16.3 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 6 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark ALPS Pharmaceutical Ind. Co., Ltd. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
ALMALENCE, INC.
6 patents
ALPAO
6 patents
ALPHA EC INDUSTRIES 2018 S.A.R.L.
6 patents
ALPINA RAGGI S.P.A.
6 patents
ALTAN ROBOTECH INC.
6 patents
ALTAROCK ENERGY INC.
6 patents
ALTESSE
6 patents
ALTIMATE MEDICAL HOLDINGS, INC.
6 patents
ALPS Pharmaceutical Ind. Co., Ltd.
6 patents
What this shows ALPS holds 6 patents at rank #38,617, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #38,617 in granted patent volume.
Other assignees with the most granted patents in ALPS's primary technology class.
ALPS's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
27 Top 76% higher than 24% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 1 | 16.7% |
| 2017 | 1 | 16.7% |
| 2020 | 1 | 16.7% |
| 2021 | 2 | 33.3% |
| 2022 | 1 | 16.7% |
Top 6 of 6 technology areas
Overall rank by patents
#38,617
Across all tracked assignees
27.4 out of 100
How to use this portfolio
ALPS's 6 grants land it in the top 76% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.